drugset / Trial / NCT00005606
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
Treatment
Summary
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation. PURPOSE: Phase II trial to study the effectiveness of peripheral blood lymphocyte therapy in treating and preventing lymphoproliferative disorders in patients who have Epstein-Barr virus infection following transplantation.
Timeline
- Start
- 2000-02
- Primary completion
- 2003-09
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes | Cell therapy | — | — |
| Subject | autologous Epstein-Barr virus-specific cytotoxic T lymphocytes | Cell therapy | — | — |